<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820417</url>
  </required_header>
  <id_info>
    <org_study_id>C-225/ZD1839</org_study_id>
    <nct_id>NCT00820417</nct_id>
  </id_info>
  <brief_title>Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib</brief_title>
  <official_title>Phase 1 Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of the Combination of Cetuximab (C-225), a Chimeric Monoclonal Antibody Against the Epidermal Growth Factor Receptor (EGFR), and Gefitinib (ZD1839), a Selective EGFR Tyrosine Kinase Inhibitor, in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harrison Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Harrison Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two&#xD;
      centres on patients with advanced cancer expressing EGFR. Primary objective is the&#xD;
      determination of the maximum tolerated dose (MTD) and recommended dose (RD) of the&#xD;
      combination of intravenous Cetuximab and oral Gefitinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between 36 and 66 patients will be enrolled depending on the number of dose levels which can&#xD;
      be completed. Patients will have histologically confirmed EFGR-expressing solid malignant&#xD;
      tumours (colorectal cancer, head and neck cancer and NSCLC), which did not respond to&#xD;
      standard therapy or for which no suitable therapy exists.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of the combination intravenous Cetuximab/oral Gefitinib.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic (PK) parameters of the combination Cetuximab/Gefitinib</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacogenomic profile of study patients and to correlate the different profiles with efficacy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the possible correlation between activity and the polymorphisms of the EGFR measured in the blood and in the primary tumour</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the possible immune response related to cetuximab</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate signs of clinical activity (response rate according to the RECIST criteria)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Non Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum tolerated dose (MTD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab/Gefitinib combination and/or monotherapy</intervention_name>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent prior to inclusion&#xD;
&#xD;
          -  Confirmed histological diagnosis of non-resectable, solid, malignant, EGFR expressing&#xD;
             tumours of the following types: colorectal cancer, head and neck cancer and non-small&#xD;
             cell lung cancer (NSCLC). Advanced clinical stage III/IV which did not respond to&#xD;
             standard therapy or for which no suitable therapy exists&#xD;
&#xD;
          -  Patients with at least one evaluable lesion (evaluable disease) by the RECIST criteria&#xD;
&#xD;
          -  Availability of tumour tissue, whether from primary tumour or metastasis to determine&#xD;
             EGFR expression&#xD;
&#xD;
          -  Viability of establishing outpatient treatment&#xD;
&#xD;
          -  Effective contraception for patients of both sexes if there is a risk of conception&#xD;
&#xD;
          -  Karnofsky performance status greater than 70 %&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Adequate renal function (creatinine &lt; 1.5 x UNL), liver function (bilirubin &lt; 1.5 x&#xD;
             UNL, ALT/AST &lt; 2.5 x UNL o &lt;5 x UNL if hepatic metastasis) and adequate bone marrow&#xD;
             (leucocytes &gt; 3000/µl, absolute neutrophil count &gt; 1500/µl, platelets &gt; 100,000/µl,&#xD;
             haemoglobin &gt; 9 g/dl)&#xD;
&#xD;
          -  Patients must not have undergone chemotherapy, radiotherapy or major surgery during&#xD;
             the 3 weeks before the beginning of the study, and they must have recovered from the&#xD;
             relevant secondary effects of previous treatments&#xD;
&#xD;
          -  Patients agree to have a new biopsy after two weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any symptom of bowel obstruction and/or inflammatory bowel disease&#xD;
&#xD;
          -  Previous therapy with anti-EGFR drugs&#xD;
&#xD;
          -  Patients with known cerebral metastasis&#xD;
&#xD;
          -  Patients with known active and uncontrolled infections&#xD;
&#xD;
          -  Severe uncontrolled organic dysfunctions or metabolic disorders&#xD;
&#xD;
          -  Patients unable to give informed consent&#xD;
&#xD;
          -  Patients who do not wish to or who cannot undergo the specific study treatments and&#xD;
             the study procedures&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Patient participation in another clinical trial during the previous 30 days&#xD;
&#xD;
          -  Patients with known drug and/or alcohol abuse&#xD;
&#xD;
          -  Known hypersensitivity to chimeric MoAbs or pretreatment with MoAbs&#xD;
&#xD;
          -  Any other malignant tumour in the last two years or previously diagnosed malignant&#xD;
             tumour if there is no guarantee that it is under complete control, except for suitably&#xD;
             treated in situ cervical carcinoma or basocellular carcinoma&#xD;
&#xD;
          -  Known severe hypersensitivity to ZD1839 or any of the excipients of this product&#xD;
&#xD;
          -  Any evidence of clinically active interstitial lung disease (patients with chronic,&#xD;
             stable, radiographic changes who are asymptomatic need not to be excluded)&#xD;
&#xD;
          -  Any unresolved chronic toxicity greater than common toxicity criteria (CTC) grade 2&#xD;
             from previous anticancer therapy&#xD;
&#xD;
          -  Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's&#xD;
             Wort&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>January 9, 2009</last_update_submitted>
  <last_update_submitted_qc>January 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Josep Tabernero, MD, Head, Gastrointestinal Cancer Unit, Medical Oncology Department</name_title>
    <organization>Vall d'Hebron University Hospital</organization>
  </responsible_party>
  <keyword>cetuximab</keyword>
  <keyword>monoclonal</keyword>
  <keyword>antibody</keyword>
  <keyword>epidermal</keyword>
  <keyword>growth</keyword>
  <keyword>factor</keyword>
  <keyword>receptor</keyword>
  <keyword>EGFR</keyword>
  <keyword>Gefitinib</keyword>
  <keyword>tyrosine</keyword>
  <keyword>kinase</keyword>
  <keyword>inhibitor</keyword>
  <keyword>advanced</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

